Listed

Balchem Corp: Form 10-Q for the period ended Mar 31, 2021

Filed with the SEC on Apr 30, 2021 and accepted by EDGAR at Apr 30, 2021, 15:14 ET.

Share

Management's discussion and analysis

As filed, 15,393 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

This report contains forward-looking statements, within the meaning of Section 21E of the Exchange Act, which reflect our expectation or belief concerning future events that involve risks and uncertainties. Actions and performance could differ materially from what is contemplated by the forward-looking statements contained in this report. Factors that might cause differences from the forward-looking statements include those referred to or identified in Item 1A of the Annual Report on Form 10-K for the year ended December 31, 2020 and other factors that may be identified elsewhere in this report. Reference should be made to such factors and all forward-looking statements are qualified in their entirety by the above cautionary statements.

Overview

We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Our three reportable segments are strategic businesses that offer products and services to different markets: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, as more fully described in Note 10 of the condensed consolidated financial statements. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".

As of March 31, 2021, we had approximately 1,353 full time employees worldwide. We believe that we have been successful in attracting skilled and experienced personnel in a competitive environment. Management believes that our human capital resources are adequate to perform all business functions.

COVID-19 Response

The COVID-19 response effort has been a primary focus for us since early last year. Our focus has been on employee safety first, keeping our manufacturing sites operational, satisfying customer needs, preserving cash and ensuring strong liquidity, and responding to changes in this dynamic market environment as appropriate. To date, all of our manufacturing sites are operating at near normal conditions enabling us to supply our customers with the important products and services they need, our research and development teams are advancing our innovation efforts, and all of our other employees are effectively carrying on their responsibilities and functions remotely.

While impact on demand has not been material to our Company, we are continuing to watch the markets that we serve closely. We have stress tested our balance sheet under various significant downturn scenarios and, given our relatively low net debt position, cash on hand, access to our undrawn revolving credit facility, and expected free cash flows, we are satisfied with the strength of our balance sheet as we continue through this uncertain market environment.

Segment Results

We sell products for all three segments through our own sales force, independent distributors, and sales agents.

The following tables summarize consolidated net sales by segment and business segment earnings from operations for the three months ended March 31, 2021 and 2020:

Business Segment Net Sales Three Months Ended March 31, 2021 2020
Human Nutrition & Health $104,516 $95,508
Animal Nutrition & Health 51,148 48,641
Specialty Products 28,008 27,996
Other and Unallocated (1) 1,984 2,291
Total $185,656 $174,436
Business Segment Earnings From Operations Three Months Ended March 31, 2021 2020
Human Nutrition & Health $19,690 $12,135
Animal Nutrition & Health 5,056 8,044
Specialty Products 7,189 7,986
Other and Unallocated (1) (1,360) (1,887)
Total $30,575 $26,278

(1) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $234 and $1,272 for the first quarter of 2021 and 2020, respectively, and (ii) Unallocated amortization expense of $604 and $401 for the first quarter of 2021 and 2020, respectively, related to an intangible asset in connection with a company-wide ERP system implementation.

RESULTS OF OPERATIONS

(All amounts in thousands, except share and per share data)

Three months ended March 31, 2021 compared to three months ended March 31, 2020.

Net Earnings

(in thousands)

Three Months Ended March 31, 2021 2020 Increase (Decrease) % Change
Net sales $185,656 $174,436 $11,220 6.4%
Gross margin 58,727 55,331 3,396 6.1%
Operating expenses 28,152 29,053 (901) (3.1)%
Earnings from operations 30,575 26,278 4,297 16.4%
Other expenses 592 1,788 (1,196) (66.9)%
Income tax expense 6,572 4,722 1,850 39.2%
Net earnings $23,411 $19,768 $3,643 18.4%

26

Net Sales

(in thousands)

Three Months Ended March 31, 2021 2020 Increase (Decrease) % Change
HNH $104,516 $95,508 $9,008 9.4%
ANH 51,148 48,641 2,507 5.2%
Specialty Products 28,008 27,996 12 —%
Other 1,984 2,291 (307) (13.4)%
Total $185,656 $174,436 $11,220 6.4%
  • The increase in net sales within the HNH segment for the three months ended March 31, 2021 as compared to 2020 was driven both by strong sales growth of chelated minerals and choline nutrients, as well as higher sales within food and beverage markets.
  • The increase in net sales within the ANH segment for the three months ended March 31, 2021 compared to 2020 was primarily the result of higher sales in both Monogastric and Ruminant animal markets and a favorable impact related to changes in foreign currency exchange rates.
  • The slight increase in Specialty Products segment sales for the three months ended March 31, 2021 compared to 2020 was primarily due to higher sales of products for the medical device sterilization market and a favorable impact related to changes in foreign currency exchange rates, offset by lower sales in the plant nutrition business.
  • Sales relating to other and unallocated decreased from the prior year due to a decline in shale fracking activity.

Gross Margin

(in thousands)

Three Months Ended March 31, 2021 2020 Increase (Decrease) % Change
Gross margin $58,727 $55,331 $3,396 6.1%
% of net sales 31.6% 31.7%

Gross margin as a percentage of sales decreased for the three months ended March 31, 2021 compared to 2020 primarily due to a significant increase in certain raw material and distribution costs, partially offset by favorable mix and manufacturing efficiencies.

Operating Expenses

(in thousands)

Three Months Ended March 31, 2021 2020 Increase (Decrease) % Change
Operating expenses $28,152 $29,053 $(901) (3.1)%
% of net sales 15.2% 16.7%

The decrease in operating expenses was principally due to a decrease in transaction and integration costs, travel, bad debt expense, and amortization, partially offset by certain higher compensation-related costs.

Earnings from Operations

(in thousands)

Three Months Ended March 31, 2021 2020 Increase (Decrease) % Change
HNH $19,690 $12,135 $7,555 62.3%
ANH 5,056 8,044 (2,988) (37.1)%
Specialty Products 7,189 7,986 (797) (10.0)%
Other and unallocated (1,360) (1,887) 527 27.9%
Earnings from operations $30,575 $26,278 $4,297 16.4%
% of net sales (operating margin) 16.5% 15.1%
  • Earnings from operations for the HNH segment increased primarily due to the aforementioned higher sales, product mix, and manufacturing efficiencies, partially offset by higher raw material costs.
  • ANH segment earnings from operations decreased primarily due to increases in raw material costs and distribution costs, along with an unfavorable mix.
  • The decrease in earnings from operations for the Specialty Products segment was primarily due to increases in raw material costs and distribution costs.
  • The increase in other and unallocated was driven primarily by a decrease in transaction and integration costs, partially offset by the lower sales of product into the fracking market and higher amortization related to a company-wide ERP implementation.

Other Expenses (Income)

(in thousands)

Three Months Ended March 31, 2021 2020 Increase (Decrease) % Change
Interest expense $725 $1,696 $(971) (57.3)%
Other (income) expense, net (133) 92 (225) (244.6)%
$592 $1,788 $(1,196) (66.9)%

Interest expense for the three months ended March 31, 2021 and 2020 was primarily related to outstanding borrowings under the Credit Agreement.

Income Tax Expense

(in thousands)

Three Months Ended March 31, 2021 2020 Increase (Decrease) % Change
Income tax expense $6,572 $4,722 $1,850 39.2%
Effective tax rate 21.9% 19.3%

The effective tax rate increase was primarily due to a reduction in certain tax credits and higher enacted tax rates in several states within the United States.

FINANCIAL CONDITION

LIQUIDITY AND CAPITAL RESOURCES

(All amounts in thousands, except share and per share data)

During the three months ended March 31, 2021, there were no material changes outside the ordinary course of business in the specified contractual obligations set forth in our Annual Report on Form 10-K for the year ended December 31, 2020. We expect our operations to continue generating sufficient cash flow to fund working capital requirements and necessary capital investments. We are actively pursuing additional acquisition candidates. We could seek additional bank loans or access to financial markets to fund such acquisitions, our operations, working capital, necessary capital investments or other cash requirements should we deem it necessary to do so.

Cash

Cash and cash equivalents increased to $88,535 at March 31, 2021 from $84,571 at December 31, 2020. At March 31, 2021, the Company had $56,788 of cash and cash equivalents held by foreign subsidiaries. It is our intention to permanently reinvest these funds in foreign operations by continuing to make additional plant related investments, and potentially invest in partnerships or acquisitions; therefore, we do not currently expect to repatriate these funds in order to fund U.S. operations or obligations. However, if these funds are needed for U.S. operations, we could be required to pay additional withholding taxes to repatriate these funds. Working capital was $192,441 at March 31, 2021 as compared to $172,460 at December 31, 2020, an increase of $19,981. Working capital reflects the payment of the 2020 declared dividend in 2021 of $18,700, net payments on the revolving debt of $10,000, and capital expenditures and intangible assets acquired of $6,312.

(in thousands)

Three Months Ended March 31, 2021 2020 Increase (Decrease) % Change
Cash flows provided by operating activities $40,607 $22,565 $18,042 80.0%
Cash flows used in investing activities (6,226) (5,394) (832) (15.4)%
Cash flows used in financing activities (27,933) (8,160) (19,773) (242.3)%

Operating Activities

The increase in cash flows from operating activities was primarily due to beneficial changes in assets and liabilities and increased earnings.

Investing Activities

We continue to invest in corporate projects, improvements across all production facilities, and intangible assets. Total investments in property, plant and equipment and intangible assets were $6,312 and $5,394 for the three months ended March 31, 2021 and 2020, respectively.

Financing Activities

We borrowed $5,000 against the revolving loan and made total debt payments of $15,000 during the first quarter of 2021, resulting in $346,431 available under the Credit Agreement as of March 31, 2021.

We have an approved stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 2,581,871 shares have been purchased, and we had 19,089 shares remaining in treasury at March 31, 2021. The Company repurchases shares from employees in connection with settlement of transactions under the Company's equity incentive plans. We also intend to acquire shares from time to time at prevailing market prices if and to the extent we deem it is advisable to do so based on our assessment of corporate cash flow, market conditions and other factors.

Proceeds from stock options exercised were $2,402 and $4,435 for the three months ended March 31, 2021 and 2020, respectively. Dividend payments were $18,700 and $16,704 for the three months ended March 31, 2021 and 2020, respectively.

Other Matters Impacting Liquidity

We currently provide postretirement benefits in the form of two retirement medical plans, as discussed in Note 14 – Employee Benefit Plans. The liability recorded in other long-term liabilities on the consolidated balance sheets as of March 31, 2021 and December 31, 2020 was $1,402 and $1,374, respectively, and the plans are not funded. Historical cash payments made under these plans have typically been less than $100 per year. We do not anticipate any changes to the payments made in the current year for the plans.

On June 1, 2018, we established an unfunded, nonqualified deferred compensation plan maintained for the benefit of a select group of management or highly compensated employees. Assets of the plan are held in a rabbi trust, which are subject to additional risk of loss in the event of bankruptcy or insolvency of the Company. The deferred compensation liability as of March 31, 2021 and December 31, 2020 was $5,420 and $3,581, respectively, and was included in other long-term obligations on our balance sheet. The related rabbi trust assets were $5,319 and $3,581 as of March 31, 2021 and December 31, 2020, respectively, and were included in other non-current assets on the balance sheets.

Chemogas has an unfunded defined benefit plan. The plan provides for the payment of a lump sum at retirement or payments in case of death of the covered employees. The amount recorded for these obligations on our balance sheets as of March 31, 2021 and December 31, 2020 were $920 and $950, respectively, and were included in other long-term obligations.

Critical Accounting Policies

There were no changes to the Company's Critical Accounting Policies, as described in its December 31, 2020 Annual Report on Form 10-K, during the three months ended March 31, 2021.

Related Party Transactions

We were engaged in related party transactions with St. Gabriel CC Company, LLC during the three months ended March 31, 2021. Refer to Note 17, "Related Party Transactions".

Market risk

As filed, 2,596 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our cash and cash equivalents are held primarily in certificates of deposit and money market investment funds. In the second quarter of 2019, we entered into an interest rate swap and cross-currency swap for hedging purposes. Refer to details noted above (see Note 19). Additionally, as of March 31, 2021, our borrowings were under a revolving loan bearing interest at a fluctuating rate as defined by the Credit Agreement plus an applicable rate. The applicable rate is based upon our consolidated net leverage ratio, as defined in the Credit Agreement. A 100 basis point increase or decrease in interest rates, applied to our borrowings at March 31, 2021, would result in an increase or decrease in annual interest expense and a corresponding reduction or increase in cash flow of approximately $1,536. We are exposed to commodity price risks, including prices of our primary raw materials. Our objective is to seek a reduction in the potential negative earnings impact of raw material pricing arising in our business activities. We manage these financial exposures, where possible, through pricing and operational means. Our practices may change as economic conditions change. Additionally, as disclosed below in Part II, Item 1A, we are monitoring market risks related to the current COVID-19 pandemic very closely.

Interest Rate Risk

We have exposure to market risk for changes in interest rates, including the interest rate relating to the Credit Agreement dated. In the second quarter of 2019, we began to manage our interest rate exposure through the use of derivative instruments. All of our derivative instruments are utilized for risk management purposes, and are not used for trading or speculative purposes. We have hedged a portion of our floating interest rate exposure using an interest rate swap (see Note 19 to our consolidated financial statements). As of March 31, 2021, the notional amount of our outstanding interest rate swap was $108,569.

Foreign Currency Exchange Risk

The financial condition and results of operations of our foreign subsidiaries are reported in Euros, Canadian Dollars, Malaysian Ringgits, Singapore Dollars, Australian Dollars, and Philippine Pesos and then translated into U.S. dollars at the applicable currency exchange rate for inclusion in our consolidated financial statements. Therefore, we are exposed to foreign currency exchange risk related to these currencies. In the second quarter of 2019, we entered into a cross-currency swap, with a notional amount of $108,569, which we designated as a hedge of our net investment in Chemogas.

Controls and procedures

As filed, 962 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

(a) Evaluation of Disclosure Controls and Procedures

Prior to filing this report, we completed an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Exchange Act as of March 31, 2021. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2021.

(b) Changes in Internal Controls

There have been no changes in the internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Act) during the fiscal quarter ended March 31, 2021, that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

Risk factors

As filed, 148 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes in the Risk Factors identified in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-01-01 to 2021-03-31$185.7mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2021-01-01 to 2021-03-31$126.9mus-gaap:CostOfRevenue
Gross profit3 months2021-01-01 to 2021-03-31$58.7mus-gaap:GrossProfit
Research and development3 months2021-01-01 to 2021-03-31$2.7mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2021-01-01 to 2021-03-31$30.6mus-gaap:OperatingIncomeLoss
Income tax3 months2021-01-01 to 2021-03-31$6.6mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-01-01 to 2021-03-31$23.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2021-01-01 to 2021-03-31$0.72us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-01-01 to 2021-03-31$0.73us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-01-01 to 2021-03-3132,657,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2021-01-01 to 2021-03-31$40.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2021-01-01 to 2021-03-31$6.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid3 months2021-01-01 to 2021-03-31$18.7mus-gaap:PaymentsOfDividends
Share repurchases3 months2021-01-01 to 2021-03-31$1.6mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2021-03-31$88.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-03-31$281.2mus-gaap:AssetsCurrent
Total assetsAt period end2021-03-31$1.17bnus-gaap:Assets
Current liabilitiesAt period end2021-03-31$88.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-03-31$319.7mus-gaap:Liabilities
Shareholders' equityAt period end2021-03-31$849.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001628280-21-008430. Last ingested by Listed: Oct 24, 2026, 14:51 ET. Listed shows no prices and gives no investment advice.